Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Osteoporosis
Primary: Change in Bone Mineral Density (BMD) in HIP at 6 Months — -0.041; 0.011 grams/cm^2
Phase 2 N=63 Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
HIV Infection · Bone Loss · Osteopenia
Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml
Phase 4 N=12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Osteoporosis · Bone Loss · Spinal Cord Injury
Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline
Phase 4 N=24 Weight Loss With Risedronate for Bone Health
Bariatric Surgery Candidate · Bone Loss · Weight Loss
Primary: Number of Enrolled Participants That Completed All 24 Week Procedures — 8; 13 Participants
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
N/A N=96 Effect of Diabetic Medications on Bone Metabolism
Osteoporosis · Type 2 Diabetes Mellitus
Primary: Changes in BMD at Femoral Neck — -3.2; 0.25 percentage of change in BMD — p=<0.05
N/A N=9 Exercise Mode and Acute Bone Resorption
Osteoporosis · Aging
Primary: C-telopeptide of Type I Collagen (CTX) Change — 0.09; 0.08 ng/mL
Phase 4 N=36 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Bariatric Surgery Candidate · Bone Loss
Primary: Percentage Change in Total Hip Bone Mineral Density — 0.60; -6.44 percentage of change
Phase 4 N=6 Bone Histomorphometry in Postmenopausal Men and Women With Osteoarthritis Undergoing Total Hip Replacement
Osteoporosis
Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants
N/A N=80 Micromechanical Modeling Using Low Magnitude Mechanical Stimulation
Bone Alteration
Primary: Change in Distal Tibia Bone Quality — 1.121; -2.141 percentage of change — p=0.0481
Phase 4 N=53 Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
Osteopenia · Osteoporosis
Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change
Phase 2 N=60 Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Spinal Cord Injury · Acute Spinal Cord Injury · Bone Loss
Primary: Percent Change in Bone Mass Density (BMD) in the Hip — -2.21; -12.82 percent change in bone mass density — p=0.05
Phase 2 N=23 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
N/A N=18 Enhancing Skeletal Adaptations to PTH and Exercise
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 4 N=83 The Effects of Potassium Citrate on Bone Metabolism
Bone Diseases, Metabolic · Osteoporosis, Postmenopausal
Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 4 N=109 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Bone Loss · Osteoporosis · Breast Cancer
Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change
Phase 2 N=35 Testosterone and Growth Hormone for Bone Loss in Men
Hypopituitarism · Hypogonadism · Growth Hormone Deficiency
Primary: MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. — 0.112; 0.104; 0.119; 0.111 unitless
Phase 3 N=424 A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors
Leukemia, Lymphoblastic, Acute · Osteoporosis
Primary: Effect of Taking Calcium and Vitamin D Supplements on Bone Mineral Density (BMD) — -0.95; -0.97; -0.87; -1.04 Z-Score — p=0.86
Phase 2 N=57 The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Change in Bone Mineral Density · Change in Bone Marrow Fat Content
Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…
N/A N=44 Blood Flow and Bone Density in Healthy Adult Women
Bone Loss · Hypotensive · Lower Limb Fluid Pooling
Primary: Bone Density of Proximal Femur — -0.133; -.675; 1.3 percent change in bone density
Phase 3 N=78 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
Phase 4 N=69 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Osteoporosis
Primary: Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies — 12.43; -2.51…
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
Phase 4 N=43 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
Osteoporosis, Postmenopausal · Periodontitis
Primary: Sost Values for 6th Month — 1389.177; 1085.405; 1596.585; 2131.87 ng/ml — p=<0.01
Phase 2 N=154 A Study of LY2541546 in Women With Low Bone Mineral Density
Osteoporosis
Primary: Change From Baseline to 52 Week Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.065; 0.115; 0.142; 0.054 g/cm^2
N/A N=39 Glucocorticoids and Bone in Graves' Ophthalmopathy
Graves Ophthalmopathy
Primary: Percent Change Lumbar Spine Bone Mineral Density — 1.37 Percentage change